Fig. 2
From: Tissue expression of retinoic acid receptor alpha and CRABP2 in metastatic nephroblastomas
a Quantitative analysis of RARA immunoexpression as a function of the presence of metastasis. The box-plot represents the results of the quantitative analysis of RARA immunoexpression according to the presence of metastasis, showing RARA immunoexpression in nephroblastomas with and without metastasis. Increased immunopositivity was observed in patients with metastasis (p = 0.0247). b and c Immunohistochemical expression of RARA in nephroblastomas without (b) and with metastasis (c) (63×). d Quantitative analysis of RARA immunoexpression as a function of the initial treatment. The box-plot represents the results of the quantitative analysis of RARA immunoexpression according to the type of initial treatment, showing RARA immunoexpression in nephroblastoma samples from patients subjected to pre-surgical chemotherapy and patients subjected to surgery as initial treatment (p = 0.0330). e and f Immunohistochemical expression of RARA in nephroblastoma samples from patients subjected to surgery (e) and pre-surgical chemotherapy (f) (63×). g Semiquantitative analysis of CRABP2 immunoexpression as a function of the presence of metastasis. The box-plot represents the results of the quantitative analysis of CRABP2 immunoexpression according to the presence of metastasis, showing CRABP2 immunoexpression in nephroblastomas with and without metastasis. Increased immunopositivity was observed in patients with metastasis (p = 0.0128). h and i Immunohistochemical expression of CRABP2 in nephroblastoma without (h) and with metastasis (i) (63×)